ACADIA Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson’s Disease Psychosis
News Apr 07, 2008
ACADIA Pharmaceuticals Inc. has announced that it has initiated its second Phase III trial designed to evaluate the safety and efficacy of pimavanserin as a treatment for Parkinson’s disease psychosis (PDP).
“The start of our second Phase III pivotal trial represents another important step forward toward our goal of providing a first-in-class treatment for patients with PDP,” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA Pharmaceuticals.
Hachsell continued, “We believe pimavanserin may provide a unique combination of antipsychotic efficacy, motoric tolerability and safety and, therefore, provides the potential for an important advance in therapy for patients suffering from this debilitating disorder.”
The Phase III trial is a multi-center, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of pimavanserin in approximately 240 patients with PDP. Patients in the trial will be randomized to three different study arms, which will include two different doses of pimavanserin and one placebo arm.
Patients will receive oral doses of either pimavanserin or placebo once daily for six weeks in addition to stable doses of their existing dopamine replacement therapy. The primary endpoint of the trial is antipsychotic efficacy as measured by the Scale for the Assessment of Positive Symptoms, or SAPS. Motoric tolerability will be an important secondary endpoint in the trial and will be measured using the Unified Parkinson’s Disease Rating Scale, or UPDRS.
ACADIA is also currently conducting an open-label safety extension study under which patients who have completed either of the Phase III PDP trials will have the opportunity to enroll if, in the opinion of the physician, the patient may benefit from continued treatment with pimavanserin.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018